Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
June 03, 2014 13:06 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...
Hemispherx Biopharma Formally Collaborates With the Swiss Department of Defense, Civil Protection and Sports to Study Alferon(R) Against Tamiflu Resistant Influenza Virus Strains
May 14, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it has entered into a formal collaborative research agreement...
Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro
May 05, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 5, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication...
Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction
April 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread
August 20, 2013 11:21 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
August 09, 2013 16:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...
Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's Audit Committee
July 29, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 29, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that effective July 23, 2013, the Board of Directors of Hemispherx...